Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Dexamethasone × Endocrine × Clear all

Phase

Status

Sponsor Class

NIH 2 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 408 Lymphoid 230 Other hematologic neoplasm 152 Gastrointestinal 32 Breast 23 Genitourinary 22 Thoracic 16 CNS 16 Head & Neck 13 Tumor-Agnostic 10 Gynecologic 10 Myeloid 8 Sarcoma 6 Dermatologic 6 Other solid neoplasm 5 Other 5 Other neoplasm 1 Endocrine 1 Classical hematology 1

Conditions

Pituitary Neoplasms 1 Pituitary Diseases 1

Interventions

lutetium Lu 177 dotatate 32 Everolimus 29 Magnetic Resonance Spectroscopy 19 pembrolizumab 17 Temozolomide 14 gallium Ga 68 dotatate 13 Nivolumab 13 Cisplatin 13 lanreotide 12 3-Iodobenzylguanidine 12 lenvatinib 11 cabozantinib 11 trametinib 10 dabrafenib 10 Surgical Procedures, Operative 10 Octreotide 10 Capecitabine 10 Surveys and Questionnaires 9 Positron Emission Tomography Computed Tomography 9 Paclitaxel 8 Blood Specimen Collection 8 Bevacizumab 8 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 Sunitinib 7 Sorafenib 7 Somatostatin 7 Radiosurgery 7 Radiofrequency Ablation 7 Mitotane 7 Ipilimumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02084134 2018-04-11

Steroid

Washington University School of Medicine

Phase NA Completed

43 enrolled 8 charts

Pituitary Diseases, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡